AEYE-DS Data Show 99% Imageability in Eye Screening
Tel Aviv, Israel, September 9, 2026 AEYE announced publication of clinical-trial findings evaluating AEYE-DS, an autonomous artificial intelligence-based screening...
Stroke prevention
Advertisement
Emboline Receives FDA 510(k) Clearance for Emboliner
San Jose, California, September 9, 2026 Emboline has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...
Amgen’s Repatha Wins CHMP Support for Broader Heart Protection
THOUSAND OAKS, Calif., July 29, 2026 Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP)...
InspireMD Initiates U.S. Recall of CGuard Prime System
MIAMI, May 1, 2026 InspireMD, Inc. announced a voluntary U.S. recall of its CGuard® Prime 135 cm carotid stent...
InspireMD, Inc. Secures FDA IDE for CGUARDIANS III
MIAMI, May 1, 2026 InspireMD, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its...
Advertisements
Asundexian Shows 26% Stroke Risk Reduction in Phase III
Dateline – New Orleans, USA, Feb. 5, 2026 — Bayer announced that its investigational oral Factor XIa inhibitor asundexian...
Novo Nordisk: Ozempic® Cuts Mortality and CV Events in Real-World Study
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
Advertisement
